An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...
Zacks Investment Research on MSN
LLY trading above 50 & 200-day SMAs for 2 months: How to play the stock
Eli Lilly and Company’s LLY stock has been consistently trading above its 50-day and 200-day simple moving averages (SMAs) ...
ToolGen Inc. (KOSDAQ: 199800), a leading genome editing company based in Korea, announced today that it has entered into a strategic cross-license agreement with GenEditBio Limited ("GenEditBio"), a ...
Hosted on MSN
William Blair Downgrades Verve Therapeutics (VERV)
Fintel reports that on June 17, 2025, William Blair downgraded their outlook for Verve Therapeutics (NasdaqGS:VERV) from Outperform to Market Perform. Analyst Price Forecast Suggests 125.57% Upside As ...
Verve Therapeutics (NASDAQ:VERV – Get Free Report) was upgraded by analysts at Wall Street Zen to a “hold” rating in a report issued on Saturday. A number of other brokerages also recently weighed in ...
Verve Therapeutics has a beta of 2.23, suggesting that its stock price is 123% more volatile than the S&P 500. Comparatively, Elite Pharmaceuticals has a beta of 0.25, suggesting that its stock price ...
Eli Lilly to buy Verve Therapeutics for $10.50 per share, with total potential payout up to $13.50 per share. The $1.3 billion deal offers a 113% premium to Verve’s 30-day average stock price. The ...
Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. And for good reason. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive ...
Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic ...
Verve Therapeutics shares were 8% higher, at $4.49, after the company reported a first-quarter loss that was narrower than analysts' expectations. The biotechnology company said it had a quarterly ...
BOSTON (AP) — BOSTON (AP) — Verve Therapeutics Inc. (VERV) on Wednesday reported a loss of $31 million in its first quarter. The Boston-based company said it had a loss of 35 cents per share. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback